Choroidal neovascularisation secondary to Best's disease in a 13-year-old boy treated by intravitreal bevacizumab

Graefes Arch Clin Exp Ophthalmol. 2007 Nov;245(11):1723-5. doi: 10.1007/s00417-007-0604-7. Epub 2007 Jun 29.

Abstract

Background: To describe the effect of intravitreal bevacizumab for the treatment of choroidal neovascularisation secondary to vitelliform dystrophy of the macula (Best's disease).

Methods: A 13-year-old boy with confirmed Best's disease presented with visual acuity (VA) loss due to secondary choroidal neovascularisation (CNV). He was treated with a single injection of 1-mg bevacizumab.

Results: Best corrected VA (Snellen) fully recovered from 20/40 preoperatively to 20/20 over a period of 6 months. Optical coherence tomography (OCT) and angiography demonstrated regression of the CNV and resolution of the macular edema.

Conclusions: A single intravitreal injection of bevacizumab may be effective to induce morphologic and functional improvement in a juvenile suffering from CNV secondary to Best's disease.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Fluorescein Angiography
  • Humans
  • Injections
  • Male
  • Retinal Degeneration / complications
  • Retinal Degeneration / drug therapy*
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab